for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Health

Daiichi Sankyo's COVID-19 vaccine selected by Japanese drug discovery body

TOKYO (Reuters) - Daiichi Sankyo Co said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.

The vaccine, known as DS-5670, was picked for the second round of AMED’s program dedicated to COVID-19 research. Daiichi Sankyo is aiming to begin clinical studies of the vaccine around March 2021 in collaboration with the University of Tokyo.

Reporting by Rocky Swift; Editing by Toby Chopra

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up